Dizziness and lightheadedness on GLP-1s

Dizziness in GLP-1 prescribing information

Dizziness is easy to dismiss as "standing up too fast," but it is a labeled common reaction for Wegovy and appears in Zepbound trial tables above placebo. Lightheadedness can be orthostatic (worse on standing), metabolic (low glucose), or a sign of dehydration after days of poor intake.

This page is educational. MedlinePlus lists many dizziness causes, from inner-ear conditions to heart rhythm problems. A GLP-1 start does not cancel those other diagnoses.

Volume loss, blood pressure, and syncope

Wegovy labeling reports hypotension-related reactions in 1.3% of treated adults versus 0.4% on placebo, and syncope in 0.8% versus 0.2%. Some events were linked to GI fluid loss. People already on antihypertensives were more likely to have low-blood-pressure reactions. Zepbound tables include hypotension as an uncommon but higher-than-placebo event at some doses.

As body weight falls, the same milligram of a diuretic or ACE inhibitor may have a larger effect. That is a reason clinicians monitor vitals during medical weight management. It is not a reason to self-discontinue heart or kidney medicines.

Low blood sugar and other medicines

GLP-1 medicines lower glucose. The hypoglycemia risk rises when they are combined with insulin or a sulfonylurea, which both Wegovy and Zepbound labels emphasize. Shakiness, sweating, confusion, and dizziness can be low glucose until a check proves otherwise in people on those combinations.

Alcohol, skipped meals, and extra activity without fuel can add to the problem. People without diabetes still should not assume dizziness is "just the shot" if they are vomiting and barely eating. Dehydration and electrolyte shifts can cause the same spinning sensation.

Overlap with kidney warning signs

Acute kidney injury related to volume depletion is a labeled warning. Dizziness plus very little urine, confusion, or inability to drink is not a hydration-tip situation. It is a reason to seek care the same day. Older adults and people with existing kidney disease have less reserve.

Persistent vomiting is the usual setup. Treating only the dizziness with rest, while GI losses continue, misses the cause. See the related urinary-changes article for more on kidney-risk counseling in labels.

When to seek care

Call emergency services for fainting with injury, chest pain, neurologic deficits, or severe shortness of breath. Contact a clinician promptly for new dizziness after a dose increase, repeated near-falls, or dizziness with palpitations. Bring a home blood-pressure log if you have one. This site does not collect those readings.

Clinicians may hold a GLP-1 dose, evaluate labs, or coordinate with the clinician who manages blood-pressure or diabetes medicines. Do not increase the GLP-1 dose to "get used to" fainting. Titration is meant to improve GI tolerability, not to train the nervous system to ignore syncope.

• Emergency: fainting, stroke symptoms, chest pain, severe breathlessness, vomiting blood.
• Same-day: cannot keep fluids down, very little urine, confusion, repeated near-falls.
• Diabetes on insulin or a sulfonylurea: check glucose when dizzy.

Practical context while waiting for a visit

Until a clinician advises otherwise, many people are told to rise slowly from sitting, avoid driving if they feel faint, and sip fluids if they can tolerate them. Those are general safety ideas, not a cure. If symptoms started after an injection-site reaction with rash and swelling, think allergic reaction and seek urgent care.

Prescription GLP-1 treatment requires a licensed provider. Dizziness that interferes with work or walking is a valid reason to message that provider rather than waiting for the next refill date.

Frequently asked questions

Sources

1. [1] Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. DailyMed.
2. [2] Zepbound (tirzepatide) injection Prescribing Information. Eli Lilly. DailyMed.
3. [3] MedlinePlus. Dizziness.
4. [4] NIDDK. Prescription Medications to Treat Overweight & Obesity.
5. [5] Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes, Obesity and Metabolism. 2021.